Annual General Meeting of curasan AG advocates strategy of the company

  • Annual General Meeting approves all agenda items in accordance with management proposals
  • Supervisory Board after new elections in new composition

Aschaffenburg, 29 June 2017 – curasan AG (ISIN DE0005494538), a leading specialist for medical products in the field of orthobiologics, presented today details of its business development in 2016 and 2017 within the framework of its Annual General Meeting. Among other things, the voting shareholders also decided on the new composition of the Supervisory Board in the context of the regular elections.

In his presentation, CEO Michael Schlenk first explained in detail the current strategy of the company and pointed out to the attending shareholders (40,97 percent of the share capital of the company by the time of the voting) the importance of today’s extensive investment of the company in sales and marketing for the future viability of curasan AG. “We mainly receive positive feedback from our investors,” Schlenk says. “This confirms our course and shows us that we can convince the market.”

Among the items on the agenda, this year, in particular item 4, the new election of the Supervisory Board, emerged. As on the other agenda items, the voting shareholders also followed the management’s proposal on this point, and once again elected Dr. Detlef Wilke and as new members Dr. Tomas Kahn and Prof. Dr. Dirk Honold into the Supervisory Board. “I am very pleased that with Dr. Kahn and Prof. Dr. Honold we won two designated experts from the field of medical technology and finance with excellent networks for our company”, emphasizes Schlenk. “I expect many new impulses for our company from the new composition of the Supervisory Board.”

Specifically, Items 2 to 6 were endorsed with the following percentage share of voting shares:

Agenda item 2:        99.99 %
Agenda item 3:        99.67 %
Agenda item 4a:      93.09 %
Agenda item 4b:      99.54 %
Agenda item 4c:      99.55 %
Agenda item 5:        99.98 %
Agenda item 6:        98.49 %

Further details on the agenda items voted on and the presentation of today’s Annual General Meeting are available on the website of curasan AG at http://www.curasan.de/investors/hauptversammlung/.

Contact curasan AG:

Ingo Middelmenne
Head of Investor Relations
+49 6027 40 900-45
+49 174 90 911 90
ingo.middelmenne@curasan.com

Andrea Weidner
Head of Corporate Communications
+49 6027 40 900-51
andrea.weidner@curasan.com

 

 About curasan AG:
curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan. curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in the Research Triangle Park area, near Raleigh, N.C., USA. curasan´s innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange.